Genetic factors have been implicated in stroke risk, but few replicated associations have been reported. We conducted a genome-wide association study (GWAS) for ischemic stroke and its subtypes in 3,548 affected individuals and 5,972 controls, all of European ancestry. Replication of potential signals was performed in 5,859 affected individuals and 6,281 controls. We replicated previous associations for cardioembolic stroke near PITX2 and ZFHX3 and for large vessel stroke at a 9p21 locus. We identified a new association for large vessel stroke within HDAC9 (encoding histone deacetylase 9) on chromosome 7p21.1 (including further replication in an additional 735 affected individuals and 28,583 controls) (rs11984041; combined P = 1.87 × 10 −11 ; odds ratio (OR) = 1.42, 95% confidence interval (CI) = 1.28-1.57). All four loci exhibited evidence for heterogeneity of effect across the stroke subtypes, with some and possibly all affecting risk for only one subtype. This suggests distinct genetic architectures for different stroke subtypes.
Cerebrovascular disease (stroke) is one of the three most common causes of death and the major cause of adult chronic disability 1 . Stroke represents an increasing health problem throughout the world as the proportion of elderly individuals increases, and it is an important cause of dementia and age-related cognitive decline. Although conventional risk factors, such as hypertension, account for a substantial proportion of stroke risk, much remains unexplained 2 . Twin and family history studies suggest that genetic factors are responsible for some of this unexplained risk 3 . Stroke is a syndrome rather than a single disease, and different subtypes of stroke are caused by a number of distinct and specific disease processes. Approximately 80% of stroke is ischemic: the three most common ischemic stroke subtypes are large vessel, cardioembolic and small vessel (lacunar) stroke. Genetic epidemiological studies show heterogeneity between stroke subtypes, with the large vessel subtype being more strongly associated with family history 4 . SNPs associated with atrial fibrillation were found only to be significantly associated with cardioembolic stroke 5, 6 , and a variant on chromosome 9p21, initially associated with coronary artery disease and atherosclerosis, only associated with large vessel stroke 7 . These findings suggest that different genetic variants predispose to the different subtypes of ischemic stroke.
To date, there have been few GWAS for ischemic stroke, and few replicable associations have been identified 8 . To further understand the genetic basis of ischemic stroke, we undertook a GWAS as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2). We hypothesized that associations might be present only with specific stroke subtypes. To investigate this, individuals that had suffered a stroke (cases) were classified into stroke subtypes according to pathophysiological Trial of Organization 10172 in Acute Stroke Treatment (TOAST) classification 9 , using clinical assessment as well as brain and vascular imaging where available (see Online Methods). Association analyses were performed on all ischemic stroke cases combined (including individuals not further classified by stroke subtype) and on the three major stroke subtypes: large vessel, small vessel and cardioembolic stroke. Discovery samples were of European ancestry and were genotyped on Illumina arrays (see Online Methods). Following quality control analysis, the discovery set consisted of 3,548 cases (2,374 UK and 1,174 German) and 5,972 controls (5,175 UK WTCCC2 common controls and 797 German controls) genotyped on an overlapping set of 495,851 autosomal SNPs ( Table 1 and Online Methods). Within the individual UK and German datasets, cases and controls were well matched for ancestry (Online Methods and Supplementary Fig. 1 ). We therefore performed association analysis separately in the two groups and combined them using a fixed-effects meta-analysis approach. A two-stage replication study was performed in 5,859 cases (3, 863 European and 1,996 US) and 6,281 controls (4,554 European and 1,727 US), all of self-reported European ancestry ( Table 1 and Online Methods). Full details of the cohorts are provided in the Supplementary Note and in Supplementary Table 1 .
We show the results at previously reported loci ( Table 2 ) and the association analysis results across the autosomes (Fig. 1) . We replicated an association between cardioembolic stroke and variants close to the PITX2 gene and also a SNP in the ZFHX3 gene, both of which were initially associated with atrial fibrillation, a well-recognized risk factor for stroke 5, 6, 10 . We also replicated a previously reported association between large vessel stroke and the 9p21 region 7 . As we, and others have already reported 11, 12 , we did not confirm the previously published association between all stroke cases and variants in the 12p13 region 13, 14 .
Thirty-eight previously unreported loci showed potential association for all stroke cases or for one of the stroke subtypes in the discovery Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke The International Stroke Genetics Consortium (ISGC) 1 & the Wellcome Trust Case Control Consortium 2 (WTCCC2) 1 samples, and we further investigated these loci in the European replication samples by genotyping 43 SNPs covering these loci as well as 7 SNPs covering the previously reported loci (Supplementary Table 2 ). Thirteen of the newly identified loci and all of the previously reported loci were taken forward to replication in the US samples, where we performed genotyping of 20 SNPs covering these regions ( Supplementary Table 3 ). Most replication samples were genotyped using Sequenom assays; we used genotype imputation for those SNPs that were not directly genotyped (Online Methods and Supplementary Tables 2 and 3). A SNP on chromosome 7p21.1 (rs11984041) showed evidence of association with large vessel stroke in the discovery data (P = 1.07 × 10 −5 ) and in the joint European and US replication data in the same direction (one-sided P = 7.9 × 10 −5 ). As an additional verification, we investigated this SNP in three other collections of large vessel cases and matched controls (735 cases and 28,583 controls in total), which we refer to as stage 3 replication (see Online Methods for details). The stage 3 data also showed evidence in the same direction (one-sided P = 2.25 × 10 −4 ). Together, the combined discovery and threestage replication data provide strong evidence for association (P = 1.87 × 10 −11 ) and suggest that each copy of the A allele at rs11984041 increases the risk of large vessel stroke by approximately 1.4-fold ( Fig. 2 and Table 2 ). This SNP is located within the final intron of the HDAC9 gene. The frequency of the risk allele (A) was 9.29% and 8.78% in the UK and German discovery controls, respectively.
Standard statistical tests determined that the association between rs11984041 and the individual sets of cardioembolic and small vessel stroke cases was not significant (discovery and two-stage replication P = 0.12; OR = 1.10, 95% CI = 0.98-1.23 and P = 0.06; OR = 1.13, 95% CI = 1.00-1.28, respectively). A nonsignificant result could simply be caused by a lack of power: lack of significance in itself cannot rule out an effect in these subtypes. We investigated this potential genetic heterogeneity further by formally comparing different statistical models for the effect of the SNP on the different stroke subtypes. The models we compared were (i) a model in which the variant has no effect on risk for any of the subtypes ('null' model), (ii) a model in which the SNP has the same effect on each subtype ('same effects' model), (iii) three models in each of which the SNP has an effect on one subtype and no effect for the other two subtypes ('LVD' , 'SVD' and 'CE' models, respectively, for the effect only in large vessel, small vessel and cardioembolic stroke) and (iv) a 'correlated effects' model allowing different but correlated effects for each subtype. We undertook model comparison in a Bayesian statistical framework All, all ischemic stroke; LVD, large vessel stroke; SVD, small vessel stroke; CE, cardioembolic stroke. Note that not all strokes are classified into a subtype. a The UK discovery cohort was composed of three UK cohorts from London, Oxford and Edinburgh and used the shared WTCCC2 controls. b The Munich replication samples comprised some samples planned for the discovery GWAS where there was insufficient DNA for GWAS but sufficient amounts for replication. It used controls from a German cohort enrolled in the PROCARDIS trial. c The UK replication cohorts included samples from Aberdeen, Glasgow and Imperial as well as some samples planned for the discovery GWAS where there was insufficient DNA for GWAS but sufficient amounts for replication (see Online Methods). The UK replication cohorts used shared POBI controls genotyped as part of the WTCCC2. Chr., chromosome; all, all ischemic stroke; LVD, large vessel stroke; CE, cardioembolic stroke. For PITX2 and ZFHX3, results are given for one SNP reported in the literature and the SNP that showed the strongest association signal in the discovery cohort. For the 9p21 region, the SNP reported in the literature is also the one showing the strongest association signal in the discovery cohort. There is some overlap between samples in this study and those in previously published studies of association 5, 6, 10, 13 . A SNP in PRKCH that was associated with stroke in Japanese populations 23 l e t t e r S (see Online Methods for details) for our new association near HDAC9, as well as for the previously reported associations that we confirmed (those listed in Table 2 ). The results, based on the discovery stage and the first two stages of replication, are shown in Figure 3 . For rs11984041 at HDAC9, there was very strong evidence against the null model and both the SVD and CE models (which was not unexpected, given that we ascertained this SNP on the basis of evidence for an effect in LVD), and there was also strong evidence against the model in which the SNP has the same effect in each stroke subtype, thereby showing genetic heterogeneity across stroke subtypes at this SNP. The greatest posterior weight rested on the model in which there is only an effect for large vessel disease, with some weight on the correlated effects model in which the posterior distributions on effect size for SVD and CE were concentrated on much smaller effect sizes than for LVD.
In our data, heterogeneity was also seen at rs2383207 in the 9p21 region, a locus associated with heart disease and related phenotypes and previously associated with large vessel stroke. Most support was found for the model in which the effect sizes for the three stroke subtypes are correlated, but there was also substantial weight on the model in which there is only an effect for large vessel stroke. The same analyses in our data for the top SNPs in the regions previously associated with cardioembolic stroke (PITX2 region, rs1906599, and ZFHX3 region, rs12932445) showed strong support for the model in which these SNPs only affect risk for cardioembolic stroke. Together, these analyses provide compelling evidence for heterogeneity of genetic effects between stroke subtypes.
The association with rs11984041 in the HDAC9 gene implicates a new locus in susceptibility to stroke. Any association with stroke could be mediated via associations with intermediate cardiovascular risk factors that themselves increase large vessel stroke risk. Our study design does not allow a direct assessment of this possibility, as data for these risk factors were not available. However, to date, no associations have been reported between rs11984041 or correlated SNPs and hypertension 15 , hyperlipidemia 16 or diabetes 17 in large-scale GWAS of these risk factors.
All variants with an association signal in the region surrounding HDAC9 resided within a peak between two recombination hotspots that encompasses the tail end of HDAC9 (Fig. 4) . The downstream TWIST1 and FERD3L genes are physically relatively close to the identified peak and cannot be excluded as possible mechanisms through which genetic variants may exert cis effects on the large vessel stroke phenotype. HDAC9 is a member of a large family of genes that encode proteins that deacetylate histones, thereby regulating chromatin structure and gene transcription 18 . HDAC9 is ubiquitously expressed, with high levels of expression in cardiac tissue, muscle and brain 19 . Although known as histone deacetylases, these proteins also act on other substrates 20 and lead to both upregulation and downregulation of genes 21 .
The mechanism by which variants in the HDAC9 region increase large vessel stroke risk is not immediately clear. The specific association with this stroke subtype would be consistent with the association acting by accelerating atherosclerosis. The HDAC9 protein inhibits myogenesis and is involved in heart development 19 , although deleterious effects on systemic arteries have not yet been reported. Alternatively, it could increase risk by altering brain ischemic responses and might therefore have effects on neuronal survival. The HDAC9 protein has been shown to protect neurons from apoptosis, both by inhibiting JUN phosphorylation by MAPK10 and by repressing JUN transcription. HDAC inhibitors have been postulated as a treatment for stroke 22 .
It is not uninformative that a large GWAS (~3,500 cases and ~6,000 controls) failed to find any new associations for the combined phenotype of ischemic stroke. It may be that the genetic architecture of the disease involves fewer variants of more moderate effect than many other diseases and/or these variants may not be well tagged by the Illumina Human660W-Quad chip used in the study. On the other hand, as our data show, all the known loci exhibit genetic heterogeneity across the stroke subtypes, with at least some and possibly all affecting only a single subtype. This supports the possibility that distinct subtypes of the disease have differing genetic architecture. However, this hypothesis is based on the results from only four loci and does not exclude the possibility that future loci associated with stroke may predispose to all ischemic stroke. Clinical classification of disease into subtypes is not perfect. As errors in classification would reduce the power to detect heterogeneity, our findings of homogeneity l e t t e r S within classes indirectly reinforces the value of current classification methods. Because GWAS studies to date, including the one reported here, have had relatively small sample sizes for each disease subtype (and hence are underpowered for common variants of small effect), it remains possible and indeed is likely a priori that the range of effect sizes for each subtype will be similar to those for other common diseases. This suggests that future genetic studies should include adequate sample sizes for particular subtypes of ischemic stroke rather than for the disease as a whole. In summary, in this largest GWAS study of ischemic stroke conducted to date, we identified a new association with the HDAC9 gene region in large vessel stroke with an estimated effect size that is at the larger end for GWAS loci (OR = 1.38, 95% CI = 1.22-1.57, from replication data). We also replicated known associations with three other loci and showed genetic heterogeneity across subtypes of the disease for all four stroke loci. This genetic heterogeneity seems likely to reflect heterogeneity in the underlying pathogenic mechanisms and reinforces the need for the consideration of stroke subtypes separately in research and clinical contexts. Figure 2 Forest plot for the associations between rs11984041 and large vessel stroke in discovery and replication collections. The blue lines show the 95% confidence intervals of the log (OR) for each cohort, with the area of each square proportional to the inverse of the standard error.
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The diamonds indicate the 95% confidence interval for the discovery summary (combined UK and German discovery collections), combined across collections within each of the three replication stages, the replication summary (combined across all three replication stages) and the overall summary (all discovery and replication collections combined). Evidence was combined across collections via an inverse variance weighted fixed-effect meta-analysis. There was no evidence of heterogeneity of effect across collections (P = 0.92). Figure 3 Genetic heterogeneity of different stroke subtypes for the four loci with significant associations. (a-d) Data are shown for HDAC9 (a), PITX2 (b), the 9p21 region (CDKN2A, CDKN2B) (c) and ZFHX3 (d). Bar plots show the posterior probabilities on the models of association: no effect in any subtype (null), same effect in all subtypes, correlated effects across subtypes or subtype-specific effects. Models are a priori assumed to be equally likely. Bayes factors, which compare the evidence (marginal likelihood) between any pair of models, can be calculated as the ratio of the posterior probability assigned to each model as reported under each bar of the plot. Accompanying density plots show the marginal posterior distribution on the OR of the risk allele for each stroke subtype assuming a model of correlated effects (see Online Methods for specification of priors). These analyses were performed using both discovery and replication samples (stages 1 and 2). 
ONLINE METhOdS
Study subjects. All subjects were of self-reported European ancestry. Cases were classified into mutually exclusive etiologic subtypes according to TOAST classification 9 , which was performed in all stroke cases. The TOAST system has a category of 'etiology unknown' that includes cases in which no cause has been found as a result of insufficient investigation, as well as cases where no cause is found despite full investigation. This unknown group was not analyzed in subtype analyses described in this manuscript, which focused only on those cases for whom there were appropriate investigations to assign one of three subtypes: large vessel disease, cardioembolic and small vessel disease. The unknown cases were only included in the analyses of all ischemic stroke, which did not take into account subtype.
Our main analyses were of associations with all ischemic stroke and with the three main subtypes. We performed additional analyses in the discovery populations with young stroke (age <70 years at first stroke) and with the presence of large vessel stenosis and, separately, the presence of cardioembolic source, irrespective of assigned subtype. These last two analyses allowed inclusion of subjects whose data were excluded from individual subtype analysis because they had more than one potential stroke subtype. Details of individual populations are given in Table 1 and in the Supplementary Note. For all cohorts, recruitment of cases was approved by the relevant local ethics committee, and all participants gave informed consent.
GWAS genotyping. Samples from the cases were genotyped at the Wellcome Trust Sanger Institute (WTSI) on the Human660W-Quad (a custom chip designed by WTCCC2 comprising Human550 SNPs and ~6,000 common copy-number variants (CNVs) from the Structural Variation Consortium 24 ). Samples from UK control collections were genotyped on the Human1.2M-Duo (a WTCCC2 custom array comprising Human1M-Duo SNPs and the CNV content described above). Bead intensity data were processed and normalized in BeadStudio (Illumina); data for successfully genotyped samples were extracted and genotypes called within collections using Illuminus 25 . German controls were genotyped on the Illumina Human550k platform, and intensity data were processed and normalized for each sample in GenomeStudio (Illumina) using the Illumina cluster file HumanHap550v3.
GWAS quality control.
For samples, quality control analysis was performed as previously described 26, 27 . We removed samples whose genome-wide patterns of diversity differed from those of the collection at large, as these differences were likely to be caused by biases or artifacts. We used a Bayesian clustering approach 28 to infer outlying individuals on the basis of call rate, heterozygosity, ancestry and average probe intensity. To obtain a set of putatively unrelated individuals, we used a hidden Markov model (HMM) to infer identity by descent and then iteratively removed individuals to obtain a set with pairwise identity by descent of <5%. To guard against sample mishandling, we removed samples if their inferred gender was discordant with recorded gender or if <90% of the SNPs genotyped by Sequenom at the beginning of sample analysis agreed with the genome-wide data. Our final discovery dataset consisted of 3,548 cases (2,374 UK and 1,174 German) and 5,972 controls (5,175 UK and 797 German) following sample quality control analysis (Supplementary Table 4) . A full breakdown of samples by cohort and subtype is in provided Table 1 . For quality control analysis of SNPs, a measure of (Fisher) information for allele frequency at each SNP was calculated using SNPTEST (see URLs). Autosomal SNPs were excluded if this information measure was below 0.98, if minor allele frequency was <0.01%, if the SNP had >5% missing data or if Hardy-Weinberg P value was <1 × 10 −20 in the case or control collections. In the 58C, UKBS and case datasets, association between SNPs and the plate on which samples were genotyped was calculated, and SNPs with a plate effect P value of <1 × 10 −6 were also excluded. An additional 45 SNPs were removed following visual inspection of cluster plots. A breakdown of the number of SNPs excluded is provided in Supplementary Table 5 . Only SNPs genotyped in all the case and control collections were considered, leaving 495,851 autosomal SNPs after quality control. Hardy-Weinberg P values for the SNPs taken to replication are given in Supplementary Table 6 .
Initial replication genotyping and quality control. Genotyping of European replication samples was carried out at the WTSI using Sequenom iPLEX Gold assays, and genotyping of the US samples was performed at the Broad Institute using the Sequenom platform, with the exception of the GEOS study, for which genotyping was carried out using Illumina HumanOmni1-Quad chips. Imputation to HapMap 3 using the BEAGLE software program 29 was performed. Individual samples were excluded from analysis if they had call rates of <80% or if reported gender was discordant with gender-specific markers. We removed pairs of samples showing concordance indicative of being duplicates.
The PoBI samples were genotyped on the custom Human1.2M-Duo array using the Illumina Infinium platform and subjected to similar quality control as described above. For each SNP used in replication the cluster plot was visually inspected.
The PROCARDIS controls were genotyped with the Illumina HumanHap610-Quad chip. Principal-component analysis (PCA) with HapMap 2 reference population data allowed exclusion of individuals with non-European ancestry. Subsequent PCA with HapMap 3 data on German stroke samples with GWAS data and additional European reference population data showed German PROCARDIS controls had similar ancestry to German stroke cases (data not shown).
Association analysis.
We performed single SNP analysis separately in the UK and German discovery datasets under an additive model (on the log (OR)) using missing data likelihood score tests as implemented in SNPTEST. We conducted a fixed-effects meta-analysis in R to combine the evidence of association, averaging the estimated effect size parameters associated with genotype risk across the two datasets and weighting the effect size estimates by the inverse of the square of corresponding standard errors. P values were calculated assuming the combined data z score to be normally distributed. The UK and German cohorts had an inflation factor ranging from 1.014 to 1.058 and from 1.011 to 1.044, respectively, depending on the stroke subtype considered ( Supplementary  Fig. 1 ). This analysis was also performed separately in males and females.
We also conducted a genome-wide analysis based on a Bayesian model that allows each stroke subtype to have its own effect and models relationships between these effects using a hierarchical prior specification. The same effects were assumed for the corresponding stroke subtype in both the UK and German populations ( Supplementary Table 2 ).
Finally, we performed a genome-wide scan using GENECLUSTER 30 . This estimates the genealogical tree of a case-control series at a position of interest selected on the basis of the genealogy of the reference panel (HapMap 2 Utah residents of Northern and Western European ancestry (CEU) in our study) by simultaneously phasing and clustering the case and control haplotypes to the tips of the reference genealogy. The method detects signals of association in the form of differential clustering of cases and controls underneath a branch or a number of branches in the estimated genealogy, which is equivalent to associations due to haplotype effects or allelic heterogeneity (Supplementary Table 2 ). Stages 1 and 2 replication. Replication of potential associations found in the GWAS of the discovery cohorts was conducted in two stages in independent European and US samples. We investigated in the European replication cohorts 50 SNPs, that either were in loci reported in the literature from previous GWAS or showed potential associations (P < 1 × 10 −5 ) with all stroke or one of the stroke subtypes in analysis of the discovery dataset with consistent direction of effect in both the UK and German cohorts ( Supplementary Table 2 ). This threshold was chosen on the basis of resources available for replication. After analysis of the combined results of the discovery and European replication populations, 20 of these SNPs were taken forward to a second stage of replication in the US samples ( Supplementary Table 3 ).
Association analysis was performed in each replication cohort separately via a logistic regression assuming an additive genetic model. Evidence of association across the replication data were combined using a fixed-effects metaanalysis. Data on the presence or absence of a cardioembolic source or large vessel stenosis (irrespective of assigned TOAST subtype) were not available in all replication cohorts. For replication of SNPs identified because of association with cardioembolic source or large vessel stenosis in the discovery cohorts, we assessed association in the replication cohorts with the cardioembolic or large vessel stroke subtypes, respectively.
Stage 3 replication of rs11984041.
For the deCODE cases and controls, genotyping was performed on Illumina 317k or 370k chips. The rs11984041 SNP
